Pliant Therapeutics Inc (PLRX) - Total Liabilities
Based on the latest financial reports, Pliant Therapeutics Inc (PLRX) has total liabilities worth $42.95 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PLRX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Pliant Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Pliant Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PLRX asset base.
Pliant Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Pliant Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advanced Lithium Electrochemistry Cayman Co Ltd
TWO:5227
|
Taiwan | NT$291.74 Million |
|
Song Shang Electronics Co Ltd
TWO:6156
|
Taiwan | NT$3.74 Billion |
|
Global Education Limited
NSE:GLOBAL
|
India | Rs135.55 Million |
|
Amogreentech Co.Ltd
KQ:125210
|
Korea | ₩108.59 Billion |
|
Seafco Public Company Limited
BK:SEAFCO
|
Thailand | ฿1.01 Billion |
|
Kamat Hotels (I) Limited
NSE:KAMATHOTEL
|
India | Rs3.48 Billion |
|
ALBIS Leasing AG
XETRA:ALG
|
Germany | €197.53 Million |
|
Mospec Semiconductor Corp
TW:2434
|
Taiwan | NT$225.70 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Pliant Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Pliant Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pliant Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pliant Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Pliant Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $44.02 Million | -52.60% |
| 2024-12-31 | $92.87 Million | +140.73% |
| 2023-12-31 | $38.58 Million | +3.51% |
| 2022-12-31 | $37.27 Million | +68.22% |
| 2021-12-31 | $22.16 Million | +77.75% |
| 2020-12-31 | $12.46 Million | -89.57% |
| 2019-12-31 | $119.50 Million | +77.27% |
| 2018-12-31 | $67.41 Million | +2014.52% |
| 2017-12-31 | $3.19 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more